ACT funds and has direct access to the established TAP and IMPACT trials networks as well as immediate access to globally recognised haemato-oncology key opinion leaders across the UK.
Early engagement with us is proven to help with clinical development plans, study design and regulatory hurdles. All surplus income is utilised to support projects that benefit patients.
Prof. Charles Craddock
Founder
UK Blood Cancer Clinical Trials Customised to your needs
Direct Access to over 27 Research Centres across the UK embedded within the NHS
ACT funds the established and globally significant UK trials networks TAP and IMPACT.
Both networks have a strong track record of accelerated recruitment to practice informing drug, transplant and cell therapy trials. Gaining immediate access to our networks saves considerable time and resources, both in the set-up and management of your clinical trial and enables ongoing access to expert advice.
Prof. Chris Fox
Medical Director
Dr Pramila Krishnamurthy
Deputy Medical Director
Prof. Steven Knapper
Deputy Medical Director
Dr Wendy Ingram
Medical Director
Dr Victoria Potter
Medical Director
Our services
Haemato-oncology and UK Healthcare experts specialising in blood cancer trials ranging from new drug and combination studies to stem cell transplant and cellular therapy trials. Through expert knowledge and medical expertise as apply our know-how to the most complex studies to deliver transformative outcomes for the haemato-oncology community through the following:
We deliver a full suite of services depending on the need, from comprehensive clinical trial management to specific bespoke operational requirements
Reinvestment in the UK haemato-oncology trials infrastructure for further patient benefit
An emphasis on speed and efficiency
Direct, single point of access to leading research centres, opinion leading investigators and research nurses with a track record of efficient trial delivery
A diverse catchment population of around 20 million
Embedded world-class genomics, diagnostics and other translational science to generate practice changing data and support regulatory submissions
Support for regulatory and HTA submissions
Investigator initiated and industry-sponsored trials
- Signal seeking
- Registrational quality data
- Identify novel therapeutic indications
- Support for reimbursement and patient access
Testimonials
“I want to thank the whole ACT and IMPACT network for your great collaboration throughout the time we were working together. There was much support and many good communications, as mentioned to many of you I always perceived the communication with all of you as outstanding. Thank you for everything! We were honoured that we got the opportunity to work with you on this trial”
Elisabeth Kueenburg
Chief Medical Officer at Priothera
“There has never been a greater need for clinical trials of new therapies in lymphoma. I am therefore delighted that ACT’s commitment to fund the TAP and IMPACT networks will increase trial capacity in the UK and at the same time permit the delivery of registration enabling trials by UK clinicians. Our patients will benefit from such innovation”
Dr Kate Cwynarski
Consultant Haematologist and Clinical Lead Lymphoma at UCLH
“ACT’s innovative structure and ability to accelerate the delivery of practice informing trials in conjunction with the UK haematology-oncology community will be of real benefit to blood cancer patients for whom new and more effective therapies are so urgently needed”
Prof Graham Jackson
Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust
“At a time of rapid therapeutic innovation in blood cancers, new trial delivery models such as ACT are urgently needed. I am impressed with ACT’s delivery to work with world class laboratories to deliver a truly transformative clinical trials proposition at pace”
Prof Paresh Vyas
Professor of Haematology at Oxford University